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Abstract (max 300 words) 
Most cancers of various tissue origin show large portions suffering from permanent or transient 
hypoxia, which takes place during tumor development. This situation leads to an increase of the 
glycolytic metabolism leading to the production of lactate, which provides cancer cells with adequate 
amounts of energy. In order to do so, cancer cells often display an overexpression of glucose 
transporters (GLUTs), in particular of GLUT1, which results in an augmented glucose uptake. This is 
due to the fact that neoplastic cells need enhanced glucose supply to support their less efficient energy 
production by means of anaerobic glycolysis (Warburg effect). This peculiar metabolic switch can be 
effectively utilized for both diagnostic and therapeutic purposes. As a matter of fact, a widely diffused 
clinical application that exploits the increased uptake of glucose into cancerous over normal tissues 
consists in the administration of the radiolabeled glucose analogue 18F-FDG as an ubiquitous imaging 
tool for cancer diagnosis. Furthermore, therapeutic interventions aimed at reducing cancer glycolysis 
may be implemented by several strategies, such as, for example: 1) reduction of glucose uptake 
(calorie-restricted ketogenic diet, physical exercise, inhibitors of glucose transporters); 2) inhibition of 
enzymes involved in key-steps of glycolysis (hexokinase, phosphofructokinase, lactate 
dehydrogenase); 3) block of the cellular trafficking of lactate (monocarboxylate transporters); 4) 
enhancement of the mitochondrial oxidative metabolism (hyperbaric oxygen therapy, removal of 
inhibition of the Krebs cycle).  
We have developed various classes of compounds that produce an anti-proliferative effect in cancer 
cells by specific interventions on cancer metabolism. For examples, some compounds proved to be 
able to inhibit lactate dehydrogenase (LDH) activity, or to reduce glucose uptake through GLUTs. 
Furthermore, some of these compounds demonstrated a remarkable synergism with other 
antineoplastic agents with different mechanisms of action. 
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